



When to consider patient preference information along the medical product lifecycle?

An overview of decision points and situations

Eline van Overbeeke, Chiara Whichello

Karin Schölin Bywall, Rosanne Janssens, Irina Cleemput, Jonathan Mauer, Stephen Watt, Ulrik Kihlbom, Jenny Sharpe, Nikoletta Nikolenko, Berkeley Phillips, Paolo Guidi, Ketti Mazzocco, Laura Vergani, Giulia Marton, Steven Simoens, Cathy-Anne Pinto, Juhaeri Juhaeri, Bennett Levitan, Jürgen Kübler, Richard Hermann, Esther de Bekker-Grob, Jorien Veldwijk, Isabelle Huys

22 & 23 October 2018 • IMI Scientific Symposium • Brussels, Belgium

All authors confirmed no conflicts of interest. This presentation and its contents reflects the view of the presenter and not the view of PREFER, IMI, the European Union or EFPIA.



Aims & methods

	Literature review	Interviews (n=143) ^{1,2}	Validation interviews (n=11)	Focus groups (n=8) ¹
1 Identify the decision-making processes and decision points (industry, regulators, and HTA/payers)	✓	✓	✓	
2 Determine which decision points have potential to include Patient Preference Information (PPI)	✓	✓	✓	
3 Identify situations influencing the value of PPI in these decisions	✓	✓		✓

¹ Seven European countries and the US

² Patients, patient representatives, caregivers, industry representatives, regulators, HTA representatives, physicians, and academics


Results: Decision-making processes and decision points



Whichello C, Schölin Bywall K, et al. An overview of critical decision points in the medical product lifecycle: where to include patient preference information in the decision-making process? (Submitted)

Results: Situations influencing the value of PPI

3



van Overbeeke E, Whichello C, et al. Factors and situations influencing the value of patient preference studies along the medical product lifecycle: a literature review. *Drug Discovery Today*. 2018

Whichello C, van Overbeeke E, et al. Factors and situations affecting the utility of patient preference studies: semi-structured interviews in Europe and the US (submitted)

Conclusions

- 1 A total of **16 decision points** were identified throughout the MPLC
- 2 Stakeholders think **PPI is important** in decision-making, but still **no systematic approach** for collecting and using PPI
- 3 **Situations** and decisions surrounded by **uncertainties** are more **sensitive** to PPI than others

